|
|
||||
|
|
|
|
|
|
|
|||||
|
|||||
 |
 |
 |
 |
 |
| top | ||||||||||||||||||||||||||||||||
|
| 1 | Marzulene-S Combination Granules |
Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (launched in Japan at 1968, China at 1990, India at 2000 ) |
| 2 | Azuloxa Granules 2.5% |
Gastric ulcer therapeutic agent (launched in Japan at 2001, launched in Korea 2004) |
| 3 | Marzulene Combination Tablets 1.0ES |
Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2003) |
| 4 | Marzulene Combination Tablets 0.5ES |
Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2008) |
| 5 | Marzulene Combination Tablets 0.375ES |
Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2009) |
| 6 | Azuloxa Tablets 15mg |
Gastric ulcer therapeutic agent (launched in Japan at 2011) |
R&D Pipeline（2011.06.24）
| 1 | Pratosartan |
Antihypertensive agent (Phase II in Japan, Phase III in Korea) |
| 2 | ASP1941 |
Type2 Diabetes therapeutic agent (Phase III in Japan,Phase IIb in Europe,Joint development with Astellas Pharma Inc.) |
| 3 | KT6-971 |
Cholesterol absorption inhibitor (Phase II in Japan,Phase I in Europe ) |
| 4 | α-C-Galactosyl Ceramide |
Preparation of Phase I |
 |
 |
 |
 |
 |
 |